Eloxx Pharmaceuticals, Inc. (ELOX)
Oxford Ledge is still expanding full research coverage of ELOX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Eloxx develops drugs for rare genetic kidney and dermatologic diseases under strict regulatory oversight and significant competitive pressure.
SEC filings
- S-1/A Amended registration statement 2026-06-04
- S-1/A Amended registration statement 2026-06-01
- 8-K 3.02; 3.03; Departure/election of directors or officers; Amendments to articles or bylaws; Financial statements and exhibits 2026-06-01
- S-1 IPO / securities registration statement 2026-05-07
- 10-Q Quarterly financial report (unaudited) 2026-05-05
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ELOX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ELOX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.